On February 12, 2026, the FDA announced labeling changes for six menopause hormone therapy products. Risk statements about cardiovascular disease, breast cancer and probable dementia were removed from the boxed warning for the affected products.
A boxed-warning change is not a declaration that every hormone treatment is risk-free. It also does not approve compounded preparations. The practical next step is to read the current information for the exact medicine you are considering with your clinician.
Which products were listed
The FDA’s published list names Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva. They span different hormones and routes. An announcement covering these products should not be described as though every estrogen patch, every compounded cream and every hormone regimen received an identical change.
The agency maintains a page linking updated prescribing information. Use that page and the current product label, because a saved leaflet or older review may not reflect the latest revision. Brand names alone still do not explain whether a product is systemic or local.
Why the distinction matters for readers
A medicine’s warnings are intended to communicate its benefit-risk considerations. Moving or revising a boxed statement does not remove the need to discuss age, time since menopause, route and health history. People with unexplained bleeding, previous clots, certain cancers or other important conditions still need individualized assessment.
The guide to starting after 60 explains why timing remains relevant. The patch-versus-pill guide explains why route remains relevant. Neither question can be resolved solely by the presence or absence of a box on a label.
Compounded products are a separate issue
The labeling action concerned approved products. Compounded medicines remain outside FDA premarket approval for safety, effectiveness and quality. A clinic cannot use this announcement as evidence that its customized estrogen-progesterone blend has become FDA-approved.
Read bioidentical versus compounded HRT if those terms are being used together in a sales presentation. Ask about the finished prescription rather than approval of an ingredient or a different medicine.
What to bring to the next visit
Bring the exact name and packaging of your current medicine, along with any concern prompted by the news. Ask whether the updated information changes your own treatment decision, monitoring or alternatives. Do not abruptly stop, restart or change a prescription based on a headline.
If you have been avoiding care because of a warning you read years ago, it is reasonable to reopen the discussion. The answer may be a hormone treatment, a local option, a nonhormonal medicine or another assessment. The purpose of updated information is a better conversation, not a universal instruction to start treatment.
Our reporting boundary
This article summarizes the FDA’s February announcement and its listed products as checked on September 20, 2026. It is not a review of every product label or a replacement for current prescribing information. We link the agency’s announcement and product list below so you can inspect the source directly.
For the practical steps before enrollment, see the appointment checklist. Our provider reviews evaluate published service information separately from medication evidence.
FOLLOW THE EVIDENCE
Sources & further reading
Provider pages support service and price descriptions. Medical guidance supports treatment explanations. Neither is a first-hand review of patient outcomes. Checked September 20, 2026.